CITRAMEL COMPLETES PHASE IIA CLINICAL TRIAL

Breathe Easy is pleased to announce has completed the Phase IIa clinical trial of its locally developed cystic fibrosis treatment drug, Citramel™. In this study, Citramel™ demonstrated excellent safety and tolerability in participants with cystic fibrosis.

We would like to thank the trial participants for their contribution to the programme to date. We also thank the principal investigators of the study in Auckland, Christchurch, Dunedin and Waikato, and their respective teams.

With the confirmation of safety and tolerability, Breathe Easy intends to commence in Q1 a dose escalation study to determine the maximum tolerated dose for Citramel™, prior to a potential future trial cystic fibrosis and/or bronchiectasis subjects.

Breathe Easy also intends to undertake further analysis of the effects of Citramel™ on the dissolution of sputum from those with cystic fibrosis and/or bronchiectasis. This analysis may require assistance and support from the cystic fibrosis and bronchiectasis community, as will any subsequent trials to investigate the impact of higher concentrations of Citramel™ on cystic fibrosis and/or bronchiectasis subjects if they occur. Please get in touch if you are able to assist.

Comments are closed.